Phase 2 ongoing in Treatment-Resistant Depression
A double-blind, controlled, randomized phase 2 study of efficacy, safety, pharmacokinetics and pharmacodynamics of a daily oral administration of MAP4343 during 6 weeks in antidepressant-non responder’s patients experiencing a major depressive episode.

We are actively recruiting 18 to 80 year-old corresponding depressed patients at the following investigation sites in France:
Paris-Ste Anne, Paris-La Salpêtrière, Lille-Fontan, Nantes, Angers, Cholet, Tours, Poitiers, Douai, Elancourt, CHD Vendée.
and more to come.

For any query please contact us at
[email protected]